HMPL-A580

PreclinicalSmall molecule

HMPL-A580 is one of 17 small molecule programs targeting Advanced or Metastatic Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorNot yet recruiting

Solid Tumors, AdultRecruiting

Advanced or Metastatic Solid TumorPreclinical

Not yet recruiting

Solid Tumors, AdultPreclinical

Recruiting

Competition

Competitive Landscape

19 competitors in Advanced or Metastatic Solid Tumor

#DrugCompanyPhaseTrials

Cyramza

Eli Lilly

Phase 1

1 2

Abraxane

Bristol-Myers Squibb

Phase 1

1 3

Gemzar

Johnson & Johnson

Phase 1

1 4

Trodelvy

Gilead

Phase 1

1 5

Avastin

Roche

Phase 1

1 6

Adrucil

EElorac, Inc.

Phase 1

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 8

Paraplatin

AAvyxa

Phase 1

1 9

Saruparib

AstraZeneca

Phase 1

1 10

TAS 102

Taiho Oncology, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Solid Tumors, Adult

NCT07396584

Clinical

Trials by Indication[1]

Solid Tumors, Adult1 trial

A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors

Recruiting·HHutchmed·Preclinical·NCT07396584·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HMPL-A580. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMPL-A580 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMPL-A580. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchmed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHutchmed

HMPL-A580

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Solid Tumors, Adult1 trial

References

Drug Info

Quick Facts

Related News